

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	Doxycycline monohydrate
Brand Name	Apprilon®
Dosage Form(s)	40 mg modified-release (MR) capsule
Manufacturer	Galderma Canada Inc.
Submission Review	New Submission
Use Reviewed	For the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients
Common Drug Review (CDR)	CDR recommended Do Not List http://www.cadth.ca/media/cdr/complete/cdr_complete_Apprilon_April-1-13.pdf
Drug Benefit Council (DBC)	DBC met on September 9, 2013. DBC considered various inputs including: the final review by the Common Drug Review (CDR), Canadian Drug Expert Committee (CDEC) recommendation, Clinical Practice Review from one specialist and one general practitioner, 2 patient inputs, 1 caregiver input and a Budget Impact Analysis.
Drug Coverage Decision	Non-Benefit
Date	January 28, 2014
Reason(s)	Drug coverage decision is consistent with the DBC Recommendation: <ul style="list-style-type: none"> The comparative clinical benefit of 40 mg doxycycline modified-release (MR) capsules was considered uncertain due to limitations in the design and analysis of the single randomized controlled trial (RCT) comparing this dosage form with 100 mg doxycycline immediate-release (IR) capsules. Other drugs used in practice to treat rosacea (doxycycline 100 mg IR, minocycline 100 mg to 200 mg, and tetracycline 250 mg to 500 mg) are less expensive than doxycycline 40 mg MR.
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council](#) gives advice to the Ministry. The Council looks at:

- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C. and the drugs cost
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:

- advice from the Council
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

For more information about the B.C. Drug Review Process, please visit
<http://www.health.gov.bc.ca/pharmacare/outgoing/drugrevproc2.pdf>.

To find out more about the Pharmaceutical Services Division and the PharmaCare program, visit
www.health.gov.bc.ca/pharmacare.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.